Obesity Surgery

, 21:1330

Safety and Efficacy of Roux-en-Y Gastric Bypass to Treat Type 2 Diabetes Mellitus in Non-severely Obese Patients

  • Camilo Boza
  • Rodrigo Muñoz
  • José Salinas
  • Cristián Gamboa
  • Julieta Klaassen
  • Alex Escalona
  • Gustavo Pérez
  • Luis Ibañez
  • Sergio Guzmán
New Concepts

DOI: 10.1007/s11695-011-0463-5

Cite this article as:
Boza, C., Muñoz, R., Salinas, J. et al. OBES SURG (2011) 21: 1330. doi:10.1007/s11695-011-0463-5

Abstract

The efficacy of Roux-en-Y gastric bypass (RYGB) to control type 2 diabetes mellitus (T2DM) has been demonstrated in morbidly obese patients. Surgical procedures primarily focused on T2DM control in patients with body mass index (BMI) < 35 kg/m2 have shown to effectively induce remission of T2DM. However, only few reports have evaluated the safety and efficacy of RYGB in this group of patients. The aim of this study is to assess the safety and efficacy of RYGB in TD2M patients with BMI < 35 kg/m2. All T2DM patients with BMI < 35 kg/m2 and at least 12 months of follow-up who underwent laparoscopic RYGB were included. Safety of the procedure was evaluated according to mortality, need of reoperation/conversion, and complication rates. Metabolic parameters were evaluated at baseline and 6, 12, and 24 months after surgery. Thirty patients were included. Seventeen (56.6%) were women. Age, BMI, and duration of diabetes were 48 ± 9 years, 33.7 ± 1.2 kg/m2, 4 ± 2.9 years, respectively. No mortality was observed. No conversion/reoperation was needed. Average length of stay was 3.2 ± 0.9 days. Early and late postoperative complications were observed in five (16.6%) and five (16.6%) patients, respectively. Twelve months after surgery, remission was observed in 25 of 30 patients (83.3%). After 2 years, remission was achieved in 13 of 20 patients (65%), and hemoglobin A1c decreased from 8.1 ± 1.8% to 5.9 ± 1.1% and homeostasis model assessment of insulin resistance from 5.7 ± 3.2 to 1.9 ± 0.8 after 12 months. RYGB is a safe and effective procedure to induce T2DM remission in otherwise not eligible patients for bariatric surgery. Evidence from prospective studies is needed to validate this approach.

Keywords

Type 2 diabetes mellitus Gastric bypass surgery Obesity Metabolic surgery Non-severe obesity 

Copyright information

© Springer Science + Business Media, LLC 2011

Authors and Affiliations

  • Camilo Boza
    • 1
  • Rodrigo Muñoz
    • 1
    • 2
  • José Salinas
    • 1
  • Cristián Gamboa
    • 1
  • Julieta Klaassen
    • 3
  • Alex Escalona
    • 1
  • Gustavo Pérez
    • 1
  • Luis Ibañez
    • 1
  • Sergio Guzmán
    • 1
  1. 1.Department of Digestive Surgery, Faculty of MedicinePontificia Universidad Católica de ChileSantiagoChile
  2. 2.Medical Sciences PhD Program, Faculty of MedicinePontificia Universidad Católica de ChileSantiagoChile
  3. 3.Department of Nutrition and Diabetes, Faculty of MedicinePontificia Universidad Católica de ChileSantiagoChile

Personalised recommendations